Becton, Dickinson and Company (BDX)
Can Sustained Product Momentum Drive BDX Stock Before Q2 Earnings?
BD rides on Medical and Interventional product momentum, but China dynamics and research funding could weigh on second-quarter fiscal 2026 results.
Earnings Preview: Becton Dickinson (BDX) Q2 Earnings Expected to Decline
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here Are 3 Medical Supply Stocks to Consider Amid Rising Prospects
Here, we highlight three dental supplies stocks, CAH, COO and BDX, which are well positioned to generate wealth for investors amid macro uncertainty.
Becton, Dickinson: Value Or Overvalued Even Now?
Becton, Dickinson is rated a 'BUY' under $160/share, driven by attractive fundamentals and a conservative valuation approach. Despite the recent spin-off of its high-margin bioscience segment, BDX retains core medtech operations with solid profitability and robust cash flow generation. I see BDX's current 13x P/E as undervalued, with a fair value target of $215/share by 2028E and an annualized return above 15% at current prices.
Here's Why You Should Retain BDX Stock in Your Portfolio Now
BD benefits from innovation, strategic deals and strong Q1 results, but reimbursement risks and estimate cuts may temper near-term upside.
BD Unveils HemoSphere Stream for Continuous Noninvasive BP Monitoring
BDX launches HemoSphere Stream, enabling continuous non-invasive BP monitoring and boosting its advanced patient monitoring portfolio.
BD Rolls Out Next-Gen Medication Dispensing System Across Europe
BDX rolls out AI-powered Pyxis Pro and Incada platforms in Europe, aiming to boost hospital efficiency, improve medication access and elevate patient care.
3 Beaten-Down Dividend Aristocrats to Scoop Up While Wall Street Chases AI Stocks Into a Cliff
Wall Street has gotten far more selective on AI stocks, but these AI stocks are still receiving the lion's share of invested capital.
Why Is Becton Dickinson (BDX) Down 4.5% Since Last Earnings Report?
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock?
Becton, Dickinson and Company (BDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Becton, Dickinson and Company (BDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BDX Secures CE Mark for Revello Stent to Treat Iliac Artery Disease
BD wins CE Mark for its Revello vascular covered stent for iliac artery disease, expanding its peripheral vascular portfolio in the growing PAD treatment market.
BD Gains FDA Clearance for Surgiphor 1000mL Surgical Irrigation System
BDX wins FDA 510(k) clearance for Surgiphor 1000mL antimicrobial irrigation system, expanding its surgical irrigation portfolio with a powered lavage option.
